DEA Sets Hearing Date Regarding Plan to Ban Severa
Post# of 137
(Total Views: 186)
Posted On: 07/12/2022 5:38:22 PM
DEA Sets Hearing Date Regarding Plan to Ban Several Psychedelics
In January, the Drug Enforcement Administration announced a proposed ban on five psychedelics: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT. With the country going through what some have called a psychedelics renaissance, the agency received significant criticism for its proposed decision.
As such, the DEA stated in a recent notice that it will be holding a hearing on Aug. 22, 2022, to listen to testimonies from individuals who were “adversely aggrieved or affected” by its proposed ban.
The agency received plenty of backlash from researchers and advocates at the start of the year when it first proposed the ban. According to the DEA, it had taken recommendations and research from the Department of Health and Human Services, which showed that Americans were abusing the five psychedelics for their hallucinogenic properties.
The agency stated in a January notice that other federal agencies had identified cases where people were hospitalized after using two of the psychedelics and that doctors had found 5-MeO-AMT in the system of one deceased individual. The DEA acknowledged that it was unclear whether or not the psychedelic had played a role in the individual’s death.
Even so, the DEA stated that it had enough data to show that these five psychedelics had the potential for abuse and proposed classifying them as Schedule I drugs.
By the end of the commentary period, the DEA had received almost 600 messages from people requesting a hearing while others criticized the change in rules. In mid-February, the DEA administrative court conceded that the agency would have to hold hearings on the issue before it could move forward with its proposals.
Judge Teresa Wallbaum ruled that the DEA would have to issue a prehearing statement by March 28, 2022, while stakeholders, advocates and researchers who opposed the rule would have until April 27.
Although DEA administrators aren’t bound to rulings made by the Administrative Law Judges’ office, and some have ignored the court’s decrees in the past, the agency took the ruling into consideration.
The drug agency said in the recent notice that the parties that had requested the hearing intended to provide expert opinions and factual information on the reliability of the data that the DEA had used as a basis for the proposed ban. This is the first time in quite a while that a scheduling proposal has been subjected to this type of administrative arbitration.
The last time was more than 30 years in 1988 when Francis Young, an administrative law judge, challenged the agency for classifying cannabis as a Schedule I drug when it had therapeutic applications.
It is highly like that leading psychedelics industry actors such as Silo Pharma Inc. (OTCQB: SILO) will in one way or the other share their input about the planned ban. It will then be up to the DEA to act upon or ignore the feedback it receives during the upcoming hearing.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
In January, the Drug Enforcement Administration announced a proposed ban on five psychedelics: 4-OH-DiPT, 5-MeO-AMT, 5-MeO-MiPT, 5-MeO-DET and DiPT. With the country going through what some have called a psychedelics renaissance, the agency received significant criticism for its proposed decision.
As such, the DEA stated in a recent notice that it will be holding a hearing on Aug. 22, 2022, to listen to testimonies from individuals who were “adversely aggrieved or affected” by its proposed ban.
The agency received plenty of backlash from researchers and advocates at the start of the year when it first proposed the ban. According to the DEA, it had taken recommendations and research from the Department of Health and Human Services, which showed that Americans were abusing the five psychedelics for their hallucinogenic properties.
The agency stated in a January notice that other federal agencies had identified cases where people were hospitalized after using two of the psychedelics and that doctors had found 5-MeO-AMT in the system of one deceased individual. The DEA acknowledged that it was unclear whether or not the psychedelic had played a role in the individual’s death.
Even so, the DEA stated that it had enough data to show that these five psychedelics had the potential for abuse and proposed classifying them as Schedule I drugs.
By the end of the commentary period, the DEA had received almost 600 messages from people requesting a hearing while others criticized the change in rules. In mid-February, the DEA administrative court conceded that the agency would have to hold hearings on the issue before it could move forward with its proposals.
Judge Teresa Wallbaum ruled that the DEA would have to issue a prehearing statement by March 28, 2022, while stakeholders, advocates and researchers who opposed the rule would have until April 27.
Although DEA administrators aren’t bound to rulings made by the Administrative Law Judges’ office, and some have ignored the court’s decrees in the past, the agency took the ruling into consideration.
The drug agency said in the recent notice that the parties that had requested the hearing intended to provide expert opinions and factual information on the reliability of the data that the DEA had used as a basis for the proposed ban. This is the first time in quite a while that a scheduling proposal has been subjected to this type of administrative arbitration.
The last time was more than 30 years in 1988 when Francis Young, an administrative law judge, challenged the agency for classifying cannabis as a Schedule I drug when it had therapeutic applications.
It is highly like that leading psychedelics industry actors such as Silo Pharma Inc. (OTCQB: SILO) will in one way or the other share their input about the planned ban. It will then be up to the DEA to act upon or ignore the feedback it receives during the upcoming hearing.
NOTE TO INVESTORS: The latest news and updates relating to Silo Pharma Inc. (OTCQB: SILO) are available in the company’s newsroom at https://ibn.fm/SILO
Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published: https://www.PsychedelicNewsWire.com/Disclaimer
(0)
(0)